Spiral Therapeutics Raises $27M Series B to Advance Inner Ear Disorder Treatments

Spiral Therapeutics is moving in a lane most people overlook until their world starts spinning. Not metaphorically. Physically. And by then, the problem owns the room. Spiral Therapeutics, a South San Francisco-based clinical-stage biotech building therapies for inner ear disorders, just locked in $27M in Series B funding. Gund Investment led the round, with Advanced Bionics, Ferring Ventures, Uni-Bio Science Group, and a roster of returning believers doubling down. That kind of syndicate does not show up for vibes. They show up for signal.

Respect where it’s due. Congratulations to Hugo Peris, Founder and CEO, and the team for pushing a category that most people only think about when it stops working. Hearing loss. Balance disorders. Ménière’s disease. Not flashy dinner conversation, but if you’ve lived it, you know it runs the whole show.

Here’s where it gets interesting. Spiral Therapeutics is not just developing drugs. They are engineering delivery with their proprietary MICS platform, a minimally invasive system designed to get therapies exactly where they need to go inside the cochlea, and keep them there long enough to matter. In a world where drug delivery is often the silent failure point, they decided to make it the headline act.

SPT-2101, their lead program, has already shown it can reduce vertigo in clinical settings. Not theoretically. Not in a slide deck. In patients. That kind of data changes the conversation from “if” to “how fast can we move.”

The partnership with Advanced Bionics adds another layer. Devices meet therapeutics. Hardware meets biology. It is the kind of collaboration that turns incremental progress into something that actually shifts outcomes. When cochlear implants and targeted drug delivery start speaking the same language, you are not just treating symptoms, you are redefining what treatment even looks like.

From a business lens, there is a lesson hiding in plain sight. Spiral Therapeutics did not try to boil the ocean. They picked a high-need, under-addressed problem, built differentiated tech around delivery, and let clinical data do the talking. Capital tends to follow clarity, and this round is a clean example.

There is also discipline here. Years of staged funding from Savoir Capital, Camden Partners, Catalio Capital Management, and others built the runway. Then came strategic capital that actually brings something to the table. Not all money is equal. Some of it knows how to open doors you cannot even see yet.

Inner ear disorders might not trend on social feeds, but markets do not care about trends. They care about outcomes, and right now Spiral Therapeutics is quietly stacking them.